What departments does Oryzon Genomics SA have?

Oryzon Genomics SA has employees across 11 departments including Solutions Engineering, Engineering, Biotechnology, Operations, Business Development.

What is the largest department at Oryzon Genomics SA?

The largest department at Oryzon Genomics SA is Research with 4 employees.

Where are Oryzon Genomics SA employees located globally?

Oryzon Genomics SA has employees across 3 continents and 3 countries including Spain, United States Of America, Brazil.

How has Oryzon Genomics SA's team size changed over time?

Oryzon Genomics SA's team has grown from approximately 46 to 52 employees based on available data.

Oryzon Genomics SA Employee Directory

Q: Who are Oryzon Genomics SA's key employees and leadership?

Oryzon Genomics SA's key employees include: Ceo: C. B., Chief Medical Officer: R. G., Chief Scientific Officer: J. X. P., Chief Intellectual Property Officer: N. V., Chief Of Clinical Operations: S. G..

Biotechnology ResearchCatalonia, Spain51-200 Employees

Oryzon Genomics (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology/hematology. Founded in 2000 and headquartered in Barcelona, Spain, Oryzon brings together a highly experienced team accross Barcelona, Boston, and New Jersey.

The Company’s clinical portfolio is built around two differentiated LSD1 inhibitors. Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials, with very promising efficacy signals in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented at ASH 2025, with additional data expected at EHA 2026. 

Vafidemstat, its lead CNS candidate, is in clinical development across neuropsychiatric indications, including aggression in borderline personality disorder (Phase III in preparation), negative symptoms of schizophrenia (ongoing Phase IIb) and aggression in autism spectrum disorder (ASD), including genetically defined populations such as Phelan-McDermid syndrome (Phase II in preparation).

Beyond LSD1, Oryzon is expanding its pipeline to new targets such as HDAC6, with ORY-4001 nominated for potential development in neurological diseases including ALS and CMT.

Oryzon also leverages a robust biomarker platform supporting precision medicine approaches. The Company is listed on the Spanish Stock Exchange (ORY) and has attracted specialized international investors from the United States and Europe.

Oryzon Genomics SA Global Highlights

Europe
51

Spain
51

North America
6

United States Of America
6

South America
1

Brazil
1

Oryzon Genomics SA's Leadership

C. B.
Ceo
Mobile Phone
Email
R. G.
Chief Medical Officer
Mobile Phone
Email
J. X. P.
Chief Scientific Officer
Mobile Phone
Email
N. V.
Chief Intellectual Property Officer
Mobile Phone
Email
S. G.
Chief Of Clinical Operations
Mobile Phone
Email
C. M. C.
Head Of Molecular And Cell Biology Department. Drug Discovery Area
Mobile Phone
Email
J. S. S.
Head Of Pharmacology And Regulatory Toxicology
Mobile Phone
Email
T. M.
Founder And Shareholder
Mobile Phone
Email

Oryzon Genomics SA Employee Metrics

100%

50%

0%

2026

2025

Biotechnology
Business
Entrepreneurship
Analytics
Business Development
Other
Legal
Pharmaceuticals

Contact profiles from Oryzon Genomics SA

Name

Title

Contact Info

Location

Last Update

A. O. M.
Project Leader - Medicinal Chemistry
Mobile Phone
Email
SpainBarcelona
May 28, 2026
I. M. M.
Purchasing Team Leader & Hr Specialist Administrator
Mobile Phone
Email
SpainBarcelona
Oct 18, 2025
J. X.
Senior Manager
Mobile Phone
Email
May 07, 2025
R. F.
Biomedicine Scientist (project Manager)
Mobile Phone
Email
SpainCatalonia
Feb 16, 2026
F. C. D. M.
Senior Pharmacologist
Mobile Phone
Email
SpainCatalonia
Apr 14, 2026
X. P.
Compliance Officer. Responsable De Auditoría Interna
Mobile Phone
Email
SpainCatalonia
May 30, 2026
M. V.
Scientist
Mobile Phone
Email
SpainCatalonia
Apr 13, 2026
S. P.
Técnico De Laboratori
Mobile Phone
Email
SpainCatalonia
Apr 15, 2026
R. A.
Técnico De Laboratorio
Mobile Phone
Email
SpainCatalonia
Feb 16, 2026
R. C.
Dmpk & Toxicology Scientist
Mobile Phone
Email
SpainCatalonia
Apr 16, 2026

Frequently Asked Questions

What is Oryzon Genomics SA known for?

Oryzon Genomics SA was founded in 2000 operates in the Biotechnology Research industry. The company's main headquarters is located in 74 Calle de Sant Ferran Cornella de Llobregat, Catalonia 08940 Spain. Explore Oryzon Genomics SA's company overview page for more information.

What is Oryzon Genomics SA's most common email format?

Oryzon Genomics SA employees' email format typically follows the pattern of . Trying to find reliable and up-to-date employee contact data? Find more Oryzon Genomics SA email formats with LeadIQ.

How many employees does Oryzon Genomics SA have currently?

Oryzon Genomics SA has approximately 59 employees as of June 2026. These team members are located across 3 continents, including EuropeNorth AmericaSouth America.

Who are Oryzon Genomics SA's key employees and leadership?

As of June 2026, Oryzon Genomics SA's key employees include:

Ceo: C. B.
Chief Medical Officer: R. G.
Chief Scientific Officer: J. X. P.
Chief Intellectual Property Officer: N. V.
Chief Of Clinical Operations: S. G.

Looking for contact data? Unlock accurate emails and phone numbers for your ideal prospects with LeadIQ.

Everything for prospecting,
in one platform.

What you can expect from LeadIQ:

B2B data verified in real-time
Sync data to your CRM, & add it to an outreach sequence in one click
Integrations with your tech stack for optimal efficiency
A patented AI cold email generator
Account & contact-level job change tracking

Oryzon Genomics SA Employee Directory

Find Oryzon Genomics SA employees' phone numbers or email addresses

Name search is limited — try advanced search instead